Original Article

High expression of SALL4 is associated with poor prognosis in squamous cell carcinoma of the uterine cervix

Chunchan Di1*, Jing Sun4*, Hongwei Zhang2, Ping Zhou1, Jienan Kong3

Departments of 1Pathology, 2Gynecology, The First Hospital of Zibo, Zibo, Shandong, China; 3Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China; 4Department of Gynecology, Suqian Hospital of Traditional Chinese Medicine, Suqian, Jiangsu, China. *Equal contributors.

Received November 25, 2017; Accepted January 23, 2018; Epub March 1, 2018; Published March 15, 2018

Abstract: Background: The zinc-finger transcription factor Sal-like protein 4 (SALL4) plays a pivotal role in tumor invasion and metastasis. Here, we investigated the clinicopathological significance of SALL4 overexpression in cervical squamous cell carcinoma (SCC) of the uterine cervix. Methods: SALL4 immunohistochemical staining was performed on cervical SCC specimens from 129 patients, as well as 98 cases of cervical squamous intraepithelial lesion (LSIL and HSIL) and 29 normal cervix samples. SALL4 immunofluorescence staining was performed in CaSki and SiHa cervical cancer cells. Statistical analyses were applied to evaluate correlations between SALL4 overexpression and clinicopathological features of SCC patients. Survival rates were calculated using the Kaplan-Meier method, and relationships between prognostic factors and patient survival were analyzed using Cox proportional hazard models. Results: SALL4 protein showed mainly nuclear staining in cervical cancer cells. Strong diffuse SALL4 staining was frequently seen in cervical cancer compared with normal tissues. SALL4 expression was significantly higher in cervical cancers than in LSIL, HSIL, and normal cervical epithelia. SALL4 overexpression was positively correlated with poor differentiation, late-stage, and lymph node metastasis. Moreover, the 5-year survival rate of early-stage cervical cancer patients with high SALL4 expression was significantly lower than patients with low SALL4 expression. Multivariate analysis suggested that SALL4 protein expression is an independent risk factor for survival in SCC. Conclusions: SALL4 plays an important role in SCC progression. High-level SALL4 expression is an independent prognostic factor of poor outcomes in SCC.

Keywords: SALL4, immunohistochemistry, prognosis, cervical cancer

Introduction

Cervical cancer is one of the most common cancers, ranking third amongst all gynecological cancers [1]. Annually, cervical cancer has been estimated to affect 500,000 women and cause 270,000 deaths worldwide [2]. Epidemiological studies have indicated that diverse risk factors are relevant to cervical tumorigenesis, including human papilloma virus (HPV) infection, smoking, and sexual behavior [3]. High-quality screening with cytology has markedly reduced the mortality of cervical squamous cell carcinoma (SCC), which is the most frequent type of neoplasia involving the cervix [4, 5]. Surgery combined with adjuvant chemotherapy and radiotherapy are the main methods for curing this disease. Despite numerous achievements in cervical cancer treatment, it still has poor prognoses and high mortality rates following lymph node or distant organ metastasis. Thus, understanding the molecular events and mechanisms underlying tumor initiation and progression could contribute to early detection, which would facilitate cervical cancer prevention and treatment.

Sal-like protein 4 (SALL4) is a member of the SALL gene family. SALL4 is a zinc-finger transcription factor that plays an essential role in early embryonic development [6]. SALL4 was originally identified as a homeotic gene essential for head and tail determination in Drosophila and encodes a protein characterized by multi-
SALL4 in cervical carcinoma

Figure 1. Immunofluorescence staining of SALL4 protein in CaSki and SiHa cervical SCC cells. Red indicates SALL4 staining, blue indicates DAPI.

The level of SALL4 protein expression and its correlation with the clinicopathological characteristics of SCC and squamous intraepithelial lesions (low-grade intraepithelial lesions (LSILs) and high-grade intraepithelial lesions (HSILs)) have not been adequately addressed. Herein, we investigated the clinicopathological significance of SALL4 protein overexpression in cervical SCC and demonstrate its prognostic value for SCC patients.

Materials and methods

Clinical samples

Routinely processed and diagnosed uterine cervical lesions, including 29 non-neoplastic cervical tissues, 32 LSIL tissues (CIN-1), 66 HSIL tissues (CIN-2, n=35; CIN-3, n=31) and 129 SCC tissues, were collected from the Department of Pathology, the First Hospital of Zibo for SALL4 immunohistochemistry (IHC). All cervical tissue specimens were obtained from punch biopsy, LEEP or hysterectomy, and the 29 non-neoplastic cervical tissues were obtained from leiomyoma of uterus patients who underwent hysterectomy. The cancer patients were 31-79-years-old. All SCC tumor specimens were obtained from pretreatment surgical resections, and clinical data were retrieved from the patients' operative and pathological reports, while follow-up data were obtained by phone and from the outpatient clinical database. Staging was performed according to the TNM and FIGO classification of carcinomas of the uterine cervix; 77 tumors were FIGO stage I-IIA (early-stage) and 52 were stage IIB-IV (advanced-stage) according to the International Union against Cancer (UICC) criteria 7th Edition and WHO classification [25, 26]. All 129 SCC patients had follow-up records for more than 5 years, and the follow-up deadline was December 2015. Survival time was counted from the date of surgery to the follow-up deadline or date of death (usually the result of cancer recurrence or metastasis). Two experienced pathologists reviewed the hematoxylin and eosin-stained slides.

IHC

Tissue sections (4-μm thick) were deparaffinized in xylene and rehydrated. Antigen retrieve-
SALL4 in cervical carcinoma

Figure 2. SALL4 protein expression and localization in uterine cervical lesions. (A) Sall4 protein was not expressed in normal cervical squamous epithelia. (B) Sall4 protein was weakly positive in cervical SCC. (C) Sall4 protein was strongly expressed in the nucleus of cervical SCC. (D) SALL4 was expressed in the atypical cells of CIN-3. (E) Sall4 positive staining was observed in the nodal metastasis of cervical SCC. (F) Negative SALL4 protein staining in cervical SCC without metastasis. (original magnification, 200× in A-F).

Table 1. SALL4 protein expression in cervical lesions

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Case n.</th>
<th>Sall4 Positive rate (%)</th>
<th>Strongly positive rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal cervix</td>
<td>29</td>
<td>17.2%</td>
<td>0</td>
</tr>
<tr>
<td>LSIL (CIN-1)</td>
<td>32</td>
<td>65.6%**</td>
<td>12.5%</td>
</tr>
<tr>
<td>HSIL (CIN-2)</td>
<td>35</td>
<td>71.4%**</td>
<td>14.3%</td>
</tr>
<tr>
<td>HSIL (CIN-3)</td>
<td>31</td>
<td>74.2%**</td>
<td>22.6%</td>
</tr>
<tr>
<td>SCC</td>
<td>129</td>
<td>79.1%**</td>
<td>59.7%</td>
</tr>
</tbody>
</table>

LSIL: low-grade intraepithelial lesion; HSIL: high-grade intraepithelial lesion; CIN: cervical intraepithelial neoplasia; SCC: squamous cell carcinoma. **P<0.01 compared with the normal cervix.

Immunofluorescence (IF)

CaSki and SiHa cells were grown on coverslips to 70% confluence, fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.5% TritonX-100 for 10 min. Blocking was performed with 3% Albumin Bovine V (Solarbio, Beijing, China) for 1 h at room temperature. After washing with PBS, cells were incubated with anti-rabbit SALL4 (Zhongshan Golden Bridge Biotechnology, Beijing, China) at 4°C overnight, followed by incubation with Alexa Fluor® 488 goat anti-rabbit IgG (H+C) (1:1000, Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature. After wash-
SALL4 in cervical carcinoma

After washing with PBS, the cells were counterstained with 49-6-diamidino-2-phenyl-indole (DAPI) (Beyotime, Haimen, China), and the coverslips were mounted with Antifade Mounting Medium (Beyotime). IF signals were visualized and recorded using a Leica SP5II confocal microscope (Leica, Wetzlar, Germany).

Statistical analysis

All analyses were performed using SPSS 17.0 statistical package (SPSS Inc., Chicago, IL, USA). The univariate association of SALL4 protein expression and clinicopathological parameters was analyzed using the Chi-square test. Survival curves were calculated using the Kaplan-Meier method, and differences were analyzed using the log-rank test. Multivariate survival analysis was performed on all significant characteristics measured using univariate survival analysis through the Cox proportional hazard regression model. A probability value less than 0.05 was considered statistically significant.

Results

SALL4 protein expression in cervical lesions

We first performed IF to determine the subcellular localization of SALL4 protein in CaSki and SiHa SCC cells. The results reveal that SALL4 protein is primarily nuclear localized (Figure 1). By IHC, we found positive SALL4 protein expression in only 17.2% (5/29) of normal cervical tissues, but higher rates in LSIL (CIN-1, 65.6%), HSIL (CIN-2, 71.4%; CIN-3, 74.2%) and SCC (79.1%, 102/129) (P<0.01). Moreover, high-level SALL4 protein expression was observed in significantly more SCC cases (59.7%, 77/129) than normal cervical epithelia (0%, 0/29), LSIL (CIN1, 12.5%), and HSIL (CIN2, 14.3%; CIN3, 22.6%) (Figure 2; Table 1).

Association between SALL4 overexpression and clinicopathological features of cervical SCCs

SALL4 overexpression was significantly correlated with differentiation stage and lymph node metastasis. High-level SALL4 protein expression was more frequently found in poorly differentiated (74.3%, 26/35) and moderately differentiated (69.6%, 39/56) SCC compared with well-differentiated cervical SCC (31.6%, 12/38) (P<0.05). SALL4 protein expression was significantly higher in metastatic cervical SCC (80.3%, 57/71) than in non-metastatic cases (34.5%, 20/58) (P<0.01). High-level SALL4 protein expression was observed in significantly more advanced-stage cervical SCC (IIV-IV) patients (88.5%, 46/52) compared with early-stage patients (I-II) (40.3%, 31/77) (P<0.01). However, no statistical difference was found among keratinizing (56.3%, 27/48) and non-keratinizing (61.7%, 50/81) cervical SCC (P>0.05) (Table 2; Figure 3).

Table 2. Sall4 overexpression and clinicopathological features of cervical cancers

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Case n.</th>
<th>Strongly positive n. (%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological types</td>
<td>129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keratinizing</td>
<td>48</td>
<td>27 (56.3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Non-keratinizing</td>
<td>81</td>
<td>50 (61.7%)</td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td>129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poorly diff.</td>
<td>35</td>
<td>26 (74.3%)</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Moderately diff.</td>
<td>56</td>
<td>39 (69.6%)</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Well diff.</td>
<td>38</td>
<td>12 (31.6%)</td>
<td></td>
</tr>
<tr>
<td>Staging</td>
<td>129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early (I-IIA)</td>
<td>77</td>
<td>31 (40.3%)</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Late (IIB-IV)</td>
<td>52</td>
<td>46 (88.5%)</td>
<td>**</td>
</tr>
<tr>
<td>LN Metastasis</td>
<td>129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>71</td>
<td>57 (80.3%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Negative</td>
<td>58</td>
<td>20 (34.5%)</td>
<td></td>
</tr>
</tbody>
</table>

Diff.: differentiation; NS: not significant. *P<0.05, **P<0.01. *Poorly and moderately differentiated vs. well differentiated; Early stage (Stage-I + Stage-II + Stage IIIA) vs. Late stage (Stage-IIIB + Stage-III + Stage-IV).

SALL4 expression is an independent prognostic factor for SCC

All 129 SCC patients with complete survival data were identified for prognostic evaluation. Among them, 68 (52.7%) died from SCC, while 61 (47.3%) remained alive. We analyzed the prognostic value of SALL4 expression in selective patient subgroups stratified according to pTNM. Survival analyses demonstrated that high-level SALL4 expression was associated with a lower 5-year survival rate for early-stage (I-II) patients (log-rank P<0.001), but there was no association in advanced-stage (III-IV) patients (data not shown, log-rank P=0.071) (Figure 4), indicating that SALL4 protein expression might be a useful biomarker for the prognostic evaluation of cervical SCC.
Additionally, differentiation, FIGO stage, LN metastasis, and SALL4 expression were also associated with the 5-year survival rate of cervical SCC patients with high SALL4 expression by univariate analysis (Table 3). These data suggest that SALL4 could also be a valuable prognostic factor for cervical SCC. Therefore, further multivariate analysis was performed using the Cox proportional hazards model for all significant variables from the univariate analysis. We found that FIGO stage (95% CI: 1.107-2.419; P=0.014) and LN metastasis (95% CI: 1.050-2.295; P=0.027) were independent prognostic factors for survival in cervical SCC. Importantly, SALL4 overexpression also emerged as a significant independent prognostic factor for cervical SCC (95% CI: 1.101-2.444; P=0.015) (Table 3).

**Discussion**

SALL4 was first isolated from *Drosophila* and encodes a protein characterized by multiple double C2H2 zinc-finger motifs [8]. In humans, SALL4 is involved in normal development, as well as tumorigenesis. There is also research indicating that SALL4 is involved in hematopoiesis and leukemogenesis, while other studies have demonstrated that abnormal SALL4 expression is tightly linked with acute myeloid leukemia [13, 25]. SALL4 is also dysregulated and aberrantly expressed in several cancers. In germ cell tumors, such as seminomas, embryonal carcinomas and yolk sac tumors, practically uniform high-level nuclear SALL4 expression has been observed by tissue IHC, but this expression pattern is less frequently observed in teratomas and clear cell carcinomas of the ovary and endometrium [15, 19, 26].

In line with these findings, SALL4 protein was highly expressed and positively associated with advanced FIGO stage, high histological grade, lymph node involvement, distant metastasis, and recurrence in serous ovarian carcinomas [16]. Survival analyses showed that high-level SALL4 expression is associated with poorer overall and progression-free survival. Moreover, univariate and multivariate analyses showed that SALL4 is an independent prognostic marker for cervical SCC.

Li et al. [15] found that SALL4 was aberrantly expressed in primary human endometrial can-
SALL4 in cervical carcinoma

High-level SALL4 expression has been observed in human liver cancers [23], including hepatocellular carcinomas (HCCs), cholangiocarcinomas (CCs), combined hepatocellular and CCs, and fibrolamellar HCCs. Bioinformatics analyses have indicated that elevated SALL4 expression in HCC patients is associated with poor survival. Yin et al. [24] and Deng et al. [27] also reported high-level SALL4 overexpression in HCC and CC tissue specimens, respectively. Importantly, patients with higher SALL4 expression levels had worse prognoses.

Zhang et al. demonstrated that aberrant SALL4 expression was highly correlated with lymph node metastasis, and that SALL4 plays oncogenic roles in gastric cancer by modulating EMT and cell stemness [20]. Furthermore, SALL4 has been used as a marker for AFP-producing gastric carcinoma [28]. SALL4 expression is significantly higher in hepatoid adenocarcinoma than in non-hepatoid adenocarcinoma, and the combination of PLUNC, HepPar-1, and SALL4 could be a reliable prognostic indicator for gastric hepatoid adenocarcinoma. The study by Takashi et al. suggested that SALL4 is useful for diagnosing a series of gastric carcinoma variants with retro differentiation such as gastric adenocarcinoma with enteroblastic differentiation [29].

Additionally, SALL4 has been reported to be abnormally expressed in liver cancer [23, 24], lung cancer [17, 30], breast cancer [31], and esophageal SCC [18, 19, 32], indicating a direct correlation between SALL4 protein expression and the invasiveness/metastasis potential of these diseases. However, more comprehensive and systematic studies on the functional role of SALL4 in human cervical cancer are needed.

In this study, we performed IHC to analyze SALL4 protein expression in 129 cervical SCC samples, 98 precancerous samples and 9 non-neoplastic cervical tissues. Our data reveal that SALL4 protein expression is significantly higher in SCC cases, and that higher SALL4 expression is positively correlated with poor differentiation, tumor stage, and lymph node metastasis. We also found that early-stage (I-II) SCC patients with high-level SALL4 expression had lower 5-year survival rates. Univariate and multivariate analyses both showed that SALL4 overexpression is a significant independent prognostic factor in SCC. These results indicated that SALL4 is a potential predictor of poor prognosis, similar to studies focused on other

Table 3. Univariate and multivariate analyses of clinicopathological factors used to determine overall survival rates for 129 patients with cervical SCC

<table>
<thead>
<tr>
<th>Factors</th>
<th>B</th>
<th>SE</th>
<th>Wald</th>
<th>Exp(B)</th>
<th>95% CI for Exp(B)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lower</td>
<td>Upper</td>
</tr>
<tr>
<td>Univariate analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological types</td>
<td>0.131</td>
<td>0.182</td>
<td>0.519</td>
<td>1.140</td>
<td>0.798</td>
<td>1.630</td>
</tr>
<tr>
<td>Differentiation</td>
<td>0.589</td>
<td>0.195</td>
<td>9.137</td>
<td>1.802</td>
<td>1.230</td>
<td>2.640</td>
</tr>
<tr>
<td>Staging</td>
<td>0.730</td>
<td>0.183</td>
<td>15.896</td>
<td>2.076</td>
<td>1.450</td>
<td>2.973</td>
</tr>
<tr>
<td>LN Metastasis</td>
<td>0.761</td>
<td>0.181</td>
<td>17.699</td>
<td>2.141</td>
<td>1.502</td>
<td>3.053</td>
</tr>
<tr>
<td>SALL4</td>
<td>0.790</td>
<td>0.184</td>
<td>18.474</td>
<td>2.204</td>
<td>1.537</td>
<td>3.159</td>
</tr>
<tr>
<td>Multivariate analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differentiation</td>
<td>0.349</td>
<td>0.210</td>
<td>2.759</td>
<td>1.418</td>
<td>0.939</td>
<td>2.141</td>
</tr>
<tr>
<td>Staging</td>
<td>0.493</td>
<td>0.199</td>
<td>6.102</td>
<td>1.636</td>
<td>1.107</td>
<td>2.419</td>
</tr>
<tr>
<td>LN Metastasis</td>
<td>0.440</td>
<td>0.199</td>
<td>4.860</td>
<td>1.552</td>
<td>1.050</td>
<td>2.295</td>
</tr>
<tr>
<td>SALL4 expression</td>
<td>0.495</td>
<td>0.203</td>
<td>5.926</td>
<td>1.641</td>
<td>1.101</td>
<td>2.444</td>
</tr>
</tbody>
</table>

*P<0.05; **P<0.01.
SALL4 in cervical carcinoma

solid tumors [15, 16]. However, a recent study by Hao et al. [22] showed that SALL4 expression is significantly lower in colorectal cancer than in atypical hyperplasia and normal colorectal tissue. Furthermore, well-differentiated colorectal cancers expressed higher SALL4 levels than moderately- and poorly-differentiated cancers. However, SALL4 expression positively correlated with lymph node metastasis and TNM and Dukes stages. Additionally, Kilic et al. demonstrated that SALL4 expression was not found in breast tumors, serous ovarian carcinomas, or ovarian carcinomas of endometrioid or mucinous type. SCCs have been mostly negative for SALL4, with the exceptions of lung, esophagus, and anus carcinomas. In cervical cancers, adenocarcinomas of the cervix showed SALL4 positivity in 2.08% of the cases, and all showed weak nuclear staining, while SCCs and adenosquamous carcinomas were all negative for SALL4 [19]. We reviewed the study and findings, and speculate that since the previous study did not contain clinicopathological information of cases, FIGO stage, or histological grade, and a sampling error may be possible.

In conclusion, our results suggest that SALL4 is significantly overexpressed in cervical SCC tissues, and that staining intensity correlates with adverse SCC progression and prognostic markers. However, the molecular mechanisms of SALL4 that are responsible for cervical tumor progression remain to be elucidated, and additional studies are warranted regarding the role of SALL4 in cervical cancer progression.

Acknowledgements

This study was funded by Medical and Health Science Technology Development Plan of Shandong (grant number 2016WS0738).

Disclosure of conflict of interest

None.

Address correspondence to: Ping Zhou, Department of Pathology, The First Hospital of Zibo, Zibo 255200, Shandong, China. E-mail: zhouping0533@163.com; Jienan Kong, Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China. E-mail: 690963445@qq.com

References

SALL4 in cervical carcinoma


